


The Cold, the Flu or INFLUENZA!

Jim Reid

Dept of General Practice and Rural Health
Dunedin School of Medicine
University of Otago



INFLUENZA

- Don't confuse with the common cold
- Symptoms may be similar BUT
those with influenza are sick
those with coryza are unwell!

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtāgo

INFLUENZA

- Fever
- Headache
- Shivering perhaps genuine rigor
- Polyarthralgia and myalgia
- Cough (non productive at first)
- Sore throat
- Rhinorrhoea
- Emotional Lability

GI symptoms

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago

INFLUENZA

Common Cold Influenza

Incubation	12 hrs – 5 days	1 – 3 days
Fever	+ or -	++
Cough	+ or -	+
Rhinitis	+	-
Polyarthralgia	-	+
Toxaemia	-	+

(After J Murtagh)

Influenza Can Be Diagnosed Clinically

← Awareness of local and community symptom clusters and risk groups

← 70% correct diagnosis with

- fever > 37.8 : plus two of
- myalgia
- sore throat
- headache
- respiratory symptoms



Te Whare Wānanga o Ōtago

INFLUENZA


Diagnosis depends on

- Symptoms and signs
- Probability - Taloia.

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago



INFLUENZA

- **Don't Forget.....Don't miss other things that can masquerade.**

INFLUENZA

Complications


- Secondary chest infection
- Pneumonia (Staph or Strep - note mortality)
- Encephalitis

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago

Health
Sciences

A decorative vertical bar on the left side of the slide. It features a central orange arrow pointing upwards, flanked by grey arrows pointing left and right. Below the orange arrow is a red arrow pointing right. The bar has a gradient from orange at the top to purple at the bottom.

INFLUENZA

Call it **IN**fluenza - Not “flu”

There is “stomach flu”, “gastric flu”, “Flu”, “Flu Bug” etc but only one


INFLUENZA

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago

What is Influenza



Influenza is

- ← a respiratory infection
- ← caused by type A & type B viruses
- ← most common in autumn & winter
- ← enters through mucous membranes - mouth, nose, eyes
- ← highly contagious - airborne
- ← severe season >20% population infected

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtāgo

No place to hide - we all have to breathe!



UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtāgo

Health
Sciences

An Outbreak

- ← Responsibility of primary care
- ← Avoid cross infection as far as possible
- ← Keep patients away from surgeries
- ← Isolate them if they arrive
- ← Separate waiting area
- ← facemask
- ← gel for hands (for what it is worth!)

UNIVERSITY
of
OTAGO




Te Whare Wānanga o Ōtago

Influenza

Types of influenza

- Clinically relevant strains are divided into type A and B
- **Type A:** Infects many different species (sea mammals, domestic fowl, swine, other farm animals, primates)
 - Responsible for epidemics and pandemics
 - The most highly mutating form
 - Type A viruses are subdivided based on the structure of their surface proteins (eg HxNy)
- **Type B:** Primarily infects humans
 - Less mutable
 - Cause regional epidemics
 - Antigenic drift but not shift

Structure of Influenza A virus



Adapted from Laver et al⁶

UNIVERSITY
of
OTAGO




Te Whare Wānanga o Ōtāgo

Health
Sciences

Neuraminidase Inhibition - New Directions

How influenza infects you:


- ← viruses cannot multiply by themselves - must take over a living cell
- ← the influenza virus multiplies in the following ways:
 - ← virus particle lands on cell in respiratory tract
 - ← particle enters cell, releases genetic material
 - ← genetic material takes over the cell forcing the production of new influenza virus
 - ← new virus particles assembled and preparation for release
 - ← Neuraminidase enables the virus to bud from the host cell



Adapted from Laver et al⁶

Neuraminidase Inhibition

- ← NAI's inhibit the release of new virus
- ← Prevent the virus from budding and spreading to other cells




Adapted from Laver et al

UNIVERSITY
of
OTAGO




Te Whare Wānanga o Ōtago



Influenza Surface Proteins

Haemagglutinin


- ← Rod Shaped
- ← Most common surface protein
- ← Responsible for viral attachment to and penetration of host cells
- ← Contains antigenic sites targeted by host immune system
- ← 15 sub types identified
- ← 3 infect humans - H1, H2, H3



Influenza Surface Proteins

Neuraminidase

- ← Mushroom shaped
- ← Second most common surface protein
- ← Plays an essential role in release and spread of virus from infected cells
- ← Major target for host antibody
- ← 9 sub types identified
- ← 2 infect humans - N1 & N2



Influenza Surface Proteins

- ← The influenza viruses are highly variable and each subtype can exist in many different strains
- ← Most parts of the surface proteins (haemagglutinin and neuraminidase) vary year by year
- ← **HOWEVER**, the active site of neuraminidase is conserved in all strains

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtāgo


PREVENTION

- ← Avoid crowded and confined areas
- ← Promote handwashing
- ← Cough and sneeze hygiene

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago

A vertical bar on the left side of the slide, transitioning from orange at the top to purple at the bottom. It features three arrows: a grey arrow pointing left at the top, a red arrow pointing right below it, and the main bar itself pointing upwards.

Prevention

THINK PREVENTION

THINK

IMMUNISATION!!!!!!


- ← Inactive vaccine - safe
- ← Strains changed regularly.

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago

Health
Sciences




Results Each cohort included more than 25,000 persons 65 years of age or older.

Immunization rates ranged from 45 percent to 58 percent. Although the vaccine recipients had more coexisting illnesses at base line than those who did not receive the vaccine, during each influenza season vaccination was associated with a reduction in the rate of hospitalization for pneumonia and influenza (by 48 to 57 percent, $P = 0.002$) and for all acute and chronic respiratory conditions (by 27 to 39 percent, $P = 0.01$). Vaccination was also associated with a 37 percent reduction ($P = 0.04$) in the rate of hospitalization for congestive heart failure during the 1991-1992 season, when influenza A was epidemic.

The Efficacy and Cost Effectiveness of Vaccination
against Influenza among Elderly Persons Living in the
Community

K.L. Nichol, K.L. Margolis, J. Wuorenma, and T. Von Sternberg *NEJM* 331:778-784; Sept22 94



Both years, during peak and total periods, vaccination reduced all causes of death and hospitalization for pneumonia and influenza: hospitalizations were reduced by 19%–20% and 18%–24% for years 1 and 2, respectively, and deaths were reduced by 60%–61% and 35%–39% for the same periods.

Influenza Vaccine Effectiveness in Preventing Hospitalizations and Deaths in Persons 65 Years or Older in Minnesota, New York, and Oregon: Data from 3 Health Plans

[James Nordin¹](#), [John Mullooly²](#), [Sung-Poblete⁴](#), et al J Inf Dis 184:6;665-670



Te Whare Wānanga o Ōtago



We included patients meeting the European Union FLI case definition and swabbed less than eight days after symptom onset. Laboratory-confirmed influenza cases were compared with negative controls. The adjusted vaccine effectiveness was 42.3% (95% CI: −7.3 to 69.0%), suggesting moderate protection of the seasonal vaccine.

Eurosurveillance, Kissling E, Reid J, Valenciano M .Volume 16, Issue 11, 17 March 2011

UNIVERSITY
of
OTAGO



Te Whare Wānanga o Ōtago

Health
Sciences



Vaccination was associated with a 56% reduction in any complication (95% CI 36–70%), a 54% reduction in hospitalizations (26–71%), and 58% reduction in deaths (13–80%). Among study subjects aged 18–64 years, we observed somewhat higher reductions in the occurrence of any complication than among those aged >65 years (72 vs. 39%).

Clinical Effectiveness of First and Repeat Influenza Vaccination in Adult and Elderly Diabetic Patients
Ingrid Looijmans-Van den Akker, MD¹, Theo J.M. Verheij, MD, PHD¹, Erik Buskens, MD, PHD¹, et al.
Diabetes Care, Aug06; 29:8; 1771-1776

UNIVERSITY
of
OTAGO




Te Whare Wānanga o Ōtago

Health
Sciences


Treatment: the earlier the better

benefit



time

Symptom onset



TREATMENT

AMANTIDINE

- ← Available in NZ (treatment of Parkinson's Disease)
- ← Reduces replication of the virus (A only)
- ← Must be used within 48 hours of onset of symptoms
- ← Is not cheap
- ← Is not without side effects
- ← May induce resistant strains
- ← And Probably does not work.

TREATMENT

Neuraminidase Inhibitors

← Zanamavir (RELENZA) – inhaled & IV


← Oseltamivir (TAMIFLU) - oral

Effective against both influenza A and B

UNIVERSITY
of
OTAGO




Te Whare Wānanga o Ōtāgo



Neuraminidase Inhibition

- ← Zanamivir and oseltamivir are in this class
- ← Block the active site of the NA protein, prevents virus budding and spreading to other cells
- ← Fewer infected cells reduces symptom severity
- ← Effective against type A and B viruses
- ← Initial lab studies suggest low incidence of resistance




Summary of treatment benefits with Oseltamivir

- 30% reduction in illness duration
- 50% less secondary complications resulting in reduced antibiotic use
- Back to usual activities two to three days faster
- 38% reduction in severity of illness



Te Whare Wānanga o Ōtago




Influenza; Groups at Higher Risk of Complications

← Elderly, especially in residential care units

← Patients with:

- chronic respiratory disease e.g. asthma, COPD
- chronic heart disease
- chronic metabolic disease e.g. diabetes mellitus
- immunosuppression due to treatment or disease
- haematological disorders
- chronic renal failure

Protective Efficacy¹




← 67% protection from influenza with any symptom

← 84% protection from influenza symptoms associated with fever

← Reduction in duration of fever when it occurred.

¹ICAAC, 1998. Accepted by JAMA

A decorative graphic on the left side of the slide. It features a vertical orange arrow pointing upwards, a grey arrow pointing to the left, and a red arrow pointing to the right, all originating from a common point at the top left.

NZ this year – so far!!

- Canterbury - Type H3N2
- Auckland - Type H1N1 and Influenza B

The rest except for isolated outbreaks (eg the Student region in Dunedin) have not constituted any major outbreaks.

But – there is time yet!